Bill SponsorBILLSPONSOR
Bill Sponsor
Politicians
Bills
House Bill 2448
117th Congress(2021-2022)
Opioid Settlement Accountability Act
Introduced
Introduced
Introduced in House on Apr 12, 2021
Overview
Text
Introduced in House 
Apr 12, 2021
Not Scanned for Linkage
About Linkage
Multiple bills can contain the same text. This could be an identical bill in the opposite chamber or a smaller bill with a section embedded in a larger bill.
Bill Sponsor regularly scans bill texts to find sections that are contained in other bill texts. When a matching section is found, the bills containing that section can be viewed by clicking "View Bills" within the bill text section.
Bill Sponsor is currently only finding exact word-for-word section matches. In a future release, partial matches will be included.
Introduced in House(Apr 12, 2021)
Apr 12, 2021
Not Scanned for Linkage
About Linkage
Multiple bills can contain the same text. This could be an identical bill in the opposite chamber or a smaller bill with a section embedded in a larger bill.
Bill Sponsor regularly scans bill texts to find sections that are contained in other bill texts. When a matching section is found, the bills containing that section can be viewed by clicking "View Bills" within the bill text section.
Bill Sponsor is currently only finding exact word-for-word section matches. In a future release, partial matches will be included.
Jump To
H. R. 2448 (Introduced-in-House)


117th CONGRESS
1st Session
H. R. 2448


To amend title XIX of the Social Security Act to prohibit the Secretary of Health and Human Services from treating any Medicaid-related funds recovered from one or more pharmaceutical companies or drug distributors with respect to opioid litigation as an overpayment under such title, and for other purposes.

IN THE HOUSE OF REPRESENTATIVES

April 12, 2021

Mr. McKinley (for himself and Ms. Kaptur) introduced the following bill; which was referred to the Committee on Energy and Commerce

A BILL

To amend title XIX of the Social Security Act to prohibit the Secretary of Health and Human Services from treating any Medicaid-related funds recovered from one or more pharmaceutical companies or drug distributors with respect to opioid litigation as an overpayment under such title, and for other purposes.

Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,

SECTION 1. Short title.

This Act may be cited as the “Opioid Settlement Accountability Act”.

SEC. 2. Prohibition on treating any Medicaid-related funds recovered from one or more pharmaceutical companies or drug distributors with respect to opioid litigation as an overpayment.

(a) In general.—Section 1903(d)(3) of the Social Security Act (42 U.S.C. 1396(d)(3)) is amended by adding at the end the following new subparagraph:

“(C) (i) Subparagraph (A) and paragraph (2)(B) may not apply to any amount recovered or paid to a State on or after December 31, 2023, as a part of a comprehensive settlement of opioid litigation between pharmaceutical manufacturers (as defined in the second sentence of section 102(15) of the Controlled Substances Act) or drug distributors (as defined in the second sentence of section 102(12) of such Act) and State attorneys general, or as a part of any individual State settlement or judgement reached in such litigation initiated or pursued by a State against one or more such companies or distributors.

“(ii) A State shall use amounts recovered or paid to the State as a part of comprehensive or individual settlement, or a judgement, described in clause (i) for—

“(I) supporting access to treatment (including medication assisted treatment) and health care services (including services provided by Federally certified opioid treatment programs or other appropriate health care providers to treat individuals with opioid use disorder and subsequent support and wrap around services that encourage employment and reintegration to society);

“(II) education related to opioid use disorder;

“(III) implementing prevention activities, including the reduction of the furnishing of opioids by health care practitioners and introduction of non-opioid pain management approaches;

“(IV) training for health care practitioners with respect to best practices for prescribing opioids, pain management, educating patients of the risk of opioid use to treat chronic and acute conditions, recognizing potential cases of substance abuse, referral of patients to treatment programs, and overdose prevention;

“(V) supporting State and Federal law enforcement actions and first responder capital equipment relating to the illegal distribution of opioids and opioid analogues; and

“(VI) any other public health-related activities and social support services (including housing, employment, child-well being, criminal justice, and emergency management) relating to addressing the opioid abuse crisis within such State, as such State determines appropriate; and

evaluating at least one of the activities described in this clause to identify effective strategies to prevent opioid abuse and substance abuse disorders.”.

(b) Retroactive effective date.—The amendment made by this section shall take effect as if enacted on January 1, 2019.